Rivaroxaban J-ROCKET sets stage for continued Bayer growth in Japan
This article was originally published in Scrip
Executive Summary
Bayer's oral Factor Xa inhibitor rivaroxaban has moved a step closer to becoming the second novel anticoagulant for stroke prevention in atrial fibrillation (SPAF) patients in Japan following a filing for what will be its initial indication in the country.